Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences Tehran Iran.
Fertility and Research Centre, School of Women's & Children's Health University of New South Wales Sydney NSW Australia.
J Am Heart Assoc. 2022 Jan 18;11(2):e022349. doi: 10.1161/JAHA.121.022349. Epub 2022 Jan 11.
Background Limited and conflicting evidence is available regarding the predictive value of adding adverse pregnancy outcomes (APOs) to established cardiovascular disease (CVD) risk factors. Hence, the objective of this study was to determine whether adding APOs to the Framingham risk score improves the prediction of CVD events in women. Methods and Results Out of 5413 women who participated in the Tehran Lipid and Glucose Study, 4013 women met the eligibility criteria included for the present study. The exposure and the outcome variables were collected based on the standard protocol. Cox proportional hazard model was used to evaluate the association of APOs and CVDs. The variant of C-statistic for survivals and reclassification of subjects into Framingham risk score categories after adding APOs was reported. Out of the 4013 eligible subjects, a total of 1484 (36.98%) women reported 1 APO, while 395 (9.84%) of the cases reported multiple APOs. Univariate proportional hazard Cox models showed the significant relations between CVD events and APOs. The enhanced model had a higher C-statistic indicating more acceptable discrimination as well as a slight improvement in discrimination (C-statistic differences: 0.0053). Moreover, we observed a greater risk of experiencing a CVD event in women with a history of multiple APOs compared with cases with only 1 APO (1 APO: hazard ratio [HR] = 1.22; 2 APOs: HR; 1.94; ≥3 APOs: HR = 2.48). Conclusions Beyond the established risk factors, re-estimated CVDs risk by adding APOs to the Framingham risk score may improve the accurate risk estimation of CVD. Further observational studies are needed to confirm our findings.
关于将不良妊娠结局(APO)添加到已确立的心血管疾病(CVD)风险因素中对预测的价值,目前的证据有限且相互矛盾。因此,本研究的目的是确定在女性中,将 APO 添加到 Framingham 风险评分中是否可以改善 CVD 事件的预测。
在参加德黑兰血脂和血糖研究的 5413 名女性中,有 4013 名女性符合本研究的纳入标准。根据标准方案收集暴露和结局变量。Cox 比例风险模型用于评估 APO 与 CVD 的关联。报告了生存的变异 C 统计量和在添加 APO 后将受试者重新分类到 Framingham 风险评分类别中的情况。在 4013 名合格受试者中,共有 1484 名(36.98%)女性报告了 1 次 APO,而 395 名(9.84%)患者报告了多次 APO。单变量比例风险 Cox 模型显示 CVD 事件与 APO 之间存在显著关系。增强模型的 C 统计量更高,表明具有更好的可接受的区分度以及稍高的区分度(C 统计量差异:0.0053)。此外,我们观察到与仅有 1 次 APO 的病例相比,具有多次 APO 病史的女性发生 CVD 事件的风险更高(1 次 APO:风险比[HR] = 1.22;2 次 APOs:HR 1.94;≥3 次 APOs:HR = 2.48)。
在已确立的风险因素之外,通过将 APO 添加到 Framingham 风险评分中重新估算 CVD 风险可以改善 CVD 的准确风险估计。需要进一步的观察性研究来证实我们的发现。